


EVEREST MEDICINES
云 頂 新 耀
Everest Medicines Limited
雲 頂 新 耀 有 限 公 司
(incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立之有限公司)
(Stock Code 股份代號: 1952)

6 September 2024

Dear non-registered holder(s) ^(Note),

**Notice of Publication of 2024 Interim Report (the “Current Corporate Communication”)
and Arrangement of Electronic Dissemination of Corporate Communications**

The English and Chinese versions of the Current Corporate Communication of Everest Medicines Limited (the “Company”) are available on the Company’s website at www.everestmedicines.com and the website of Hong Kong Exchanges and Clearing Limited (“HKEx”) at www.hkexnews.hk. For the shareholders who have selected to receive the Company’s Corporate Communication in printed version, enclosed is the Current Corporate Communication of the Company the language you have expressly chosen to receive. If you have any difficulty in receiving or gaining access to the Current Corporate Communication posted on the Company’s website for any reason, the Company will promptly upon your request send the printed version of the Current Corporate Communication to you free of charge; please write to the Company’s share registrar in Hong Kong (the “Hong Kong Share Registrar”), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong or by email to everestmedicines.ecom@computershare.com.hk.

Arrangement of Electronic Dissemination of Corporate Communications

Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) under the expansion of the paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, the Company is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the “Corporate Communications”), which means any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at www.everestmedicines.com and the website of HKEx at www.hkexnews.hk in place of printed copies. You are encouraged to proactively check the Company’s website and the HKEx website to keep up with the publication of Corporate Communications.

As a non-registered holder, you should liaise with your bank(s), broker(s), custodian(s), nominee(s) or HKSCC Nominees Limited through which your Shares are held (collectively, the “Intermediaries”) and provide your email address to your Intermediaries.

If you want to receive the Corporate Communications in printed form, please complete and return the reply form on the reverse side to the Hong Kong Share Registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong or send an email to everestmedicines.ecom@computershare.com.hk specifying your name, address and request to receive the Corporate Communications in printed form.

Should you have any queries relating to this letter, please send an email to the Hong Kong Share Registrar at everestmedicines.ecom@computershare.com.hk.

Yours faithfully,
By order of the Board
Everest Medicines Limited
Wei Fu
Chairman and Executive Director

Note: “Non-registered holder” means such person or company whose shares in the Company are held in The Central Clearing and Settlement System (CCASS) and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited to receive corporate communications of the Company. If you have sold or transferred your shares in the Company, please disregard this letter and the enclosed reply form.

各位非登記持有人 ^(附註) :

2024 年中期報告 (「本次公司通訊」) 之發布通知及以電子方式發布公司通訊之安排

雲頂新耀有限公司 (「本公司」) 本次公司通訊的中、英文版本已上載於本公司網站 www.everestmedicines.com 及香港交易及結算有限公司 (「香港交易所」) 網站 www.hkexnews.hk。若閣下之前選擇收取本公司公司通訊之印刷版本，現向閣下奉上按照閣下之前所選擇語言編製的本次公司通訊。閣下若因任何理由以致在收取或接收載於本公司網址上的本次公司通訊出現困難，本公司將於接到閣下通知後，盡快向閣下免費發送有關本次公司通訊的印刷本；閣下可以書面方式通知本公司的香港股份過戶登記處 (「香港股份過戶處」) 香港中央證券登記有限公司，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓，或電郵至 everestmedicines.ecom@computershare.com.hk。

以電子方式發布公司通訊之安排

根據自 2023 年 12 月 31 日起生效的香港聯合交易所有限公司證券上市規則 (「上市規則」) 第 2.07A 條下擴大無紙化上市機制及以電子方式發布公司通訊規定，本公司謹此通知閣下，本公司已採用以電子方式發布公司通訊 (「公司通訊」) 之安排，該公司通訊是指本公司為向其任何證券持有人提供資訊或提醒其採取行動而發布或將要發布的任何文件，包括但不限於 (a) 董事報告、年度帳目以及審計報告副本以及 (如適用) 財務摘要報告；(b) 中期報告及其中期報告摘要 (如適用)；(c) 會議通知；(d) 上市文件；(e) 通函和 (f) 委任代表表格。

請注意，所有未來公司通訊的英文版和中文版將在公司網站 www.everestmedicines.com 和香港交易所網站 www.hkexnews.hk 上提供，以代替印刷本。謹此建議閣下主動查看公司網站和香港交易所網站以留意公司通訊的發布。

作為非登記持有人，閣下應聯絡閣下持有股份的銀行、經紀、託管商、代理人或香港中央結算 (代理人) 有限公司 (統稱「中介公司」)，並向閣下的中介公司提供閣下的電子郵件地址。

若閣下希望收取公司通訊之印刷版，請填妥本函背頁之回條並交回香港股份過戶處香港中央證券登記有限公司，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓或發送電子郵件至 everestmedicines.ecom@computershare.com.hk，並註明閣下的姓名、地址以及收取公司通訊印刷版的要求。

如閣下對本函件有任何疑問，請發送電子郵件至 everestmedicines.ecom@computershare.com.hk 與香港股份過戶處聯絡。

承董事會命
雲頂新耀有限公司
主席兼執行董事
傅唯
謹啟

2024 年 9 月 6 日

附註：「非登記持有人」指該等持有公司股份並存放於中央結算及交收系統的人士或公司，透過香港中央結算有限公司不時向公司發出通知，希望收到本公司的公司通訊。如果閣下已經出售或轉讓所持有之本公司股份，則無需理會本函件及所附回條。



REPLY FORM 回條

To: Computershare Hong Kong Investor Services Limited
(the "Hong Kong Share Registrar")
17M Floor, Hopewell Centre,
183 Queen's Road East, Wan Chai, Hong Kong

致：香港中央證券登記有限公司
(「香港股份過戶處」)
香港灣仔皇后大道東 183 號
合和中心 17M 樓

REMINDER 提示

As a non-registered holder, you should liaise with your bank(s), broker(s), custodian(s), nominee(s) or HKSCC Nominees Limited through which your shares are held (collectively, the "Intermediaries") and provide your email address to your Intermediaries.

作為非登記持有人，閣下應聯絡閣下持有股份的銀行、經紀、託管商、代理人或香港中央結算（代理人）有限公司（統稱「中介公司」），並向閣下的中介公司提供閣下的電子郵件地址。

Request for Corporate Communications* in printed form / 要求收取公司通訊*印刷版

I/we would like to receive future Corporate Communications* in printed form. (Please mark "✓" in the below box if applicable)

本人/我們欲收取未來公司通訊*的印刷版。（如適用，請在以下方格內劃上「✓」號）

Name of the listed company (the "Company"): Everest Medicines Limited

上市公司（「公司」）名稱：

雲頂新耀有限公司

English Version 英文版本

Chinese Version 中文版本

English and Chinese Version 英文及中文版本

Name(s) of non-registered holder(s):

非登記持有人姓名：

Signature(s): (Note 3)

簽名：(附註 3)

(Please use ENGLISH BLOCK LETTERS 請用英文正楷填寫)

Contact number:

聯絡電話號碼：

Date:

日期：

Notes:

附註：

- This Reply Form is addressed to non-registered holder(s) ("Non-registered holder" means such person or company whose shares are held in The Central Clearing and Settlement System (CCASS) and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited that such person or company wishes to receive Corporate Communications*). 此回條乃向本公司之非登記持有人（「非登記持有人」指股份存放於中央結算及交收系統的人士或公司，已透過香港中央結算有限公司不時向本公司發出通知，表示欲收取公司通訊*）發出。
- Please complete all your details clearly. 請閣下清楚填寫所有資料。
- Any form with no box marked (✓), with no signature or otherwise incorrectly completed will be void. 如在本表格未有在方格內劃上「✓」號，或未有簽署，或在其他方面填寫不正確，則本表格將作廢。
- For the avoidance of doubt, the Company does not accept any other instructions given on this Reply Form. 為免存疑，在本回條上的任何額外指示，公司將不予處理。

* Unless otherwise specified, Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular and (f) a proxy form.

除非另有註明，公司通訊乃指公司已發出或將予發出以供其任何證券的持有人參照或採取行動的任何文件，其中包括但不限於(a) 董事報告、年度帳目以及審計報告副本以及(如適用) 財務摘要報告；(b) 中期報告及(如適用) 其中期摘要報告摘要(如適用)；(c) 會議通知；(d) 上市文件；(e) 通函和(f) 委派代表書。

PERSONAL INFORMATION COLLECTION STATEMENT

收集個人資料聲明

- "Personal Data" in this statement has the same meaning as "personal data" in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO"). 本聲明中所指的「個人資料」與香港法例第 486 章《個人資料（私隱）條例》（「《私隱條例》」）中「個人資料」的涵義相同。
- Your Personal Data provided in this Reply Form will be used in connection with the Company's electronic dissemination of Corporate Communications. Your supply of Personal Data to the Company is on a voluntary basis. In case of a failure to provide sufficient information, the Company may not be able to process your instructions and/or requests as stated in this Reply Form. 閣下於本回條所提供的個人資料將用於有關公司以電子方式發布公司通訊的事宜上。閣下是自願向公司提供個人資料。若閣下未能提供足夠資料，公司可能無法處理閣下在本回條上所述的指示及/或要求。
- Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, the Hong Kong Share Registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and will be retained for such period as may be necessary for our verification and record purposes. 公司可就任何所說明的用途或在法例規定的情況下，將閣下的個人資料披露或轉移給公司的附屬公司、香港股份過戶處、及/或其他公司或團體，並在適當期間保留該等個人資料作核實及紀錄用途。
- You have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing, by mail to the Hong Kong Privacy Officer of the Hong Kong Share Registrar at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong or by email at PrivacyOfficer@computershare.com.hk. 閣下有權根據《私隱條例》的條文查閱及/或修改閣下的個人資料。任何該等查閱及/或修改個人資料的要求均須以書面方式郵寄至香港股份過戶處（地址為香港灣仔皇后大道東 183 號合和中心 17M 樓）向香港隱私主任提出，或發送電郵至 PrivacyOfficer@computershare.com.hk。

Mailing Label 郵寄標籤

Computershare Hong Kong Investor Services Limited
香港中央證券登記有限公司
Freepost No. 簡便回郵號碼：37
Hong Kong 香港

Please cut the mailing label and stick it on an envelope to return this form to us.

No postage is necessary if posted in Hong Kong.

當閣下寄回此回條時，請將郵寄標籤剪貼於信封上。
如在本港投寄，閣下無需支付郵費或貼上郵票。